Expert Interviews

Decoding Deprescribing: Strategies and Approaches for Rational Medication Reduction
May 23, 2024

Key opinion leaders in the management of diabetes discuss the process of deprescribing, or the process of medication simplification to encourage adherence and ease of regimens in older adult populations with type 2 diabetes.

Tailoring Treatment: Patient Factors Guiding First-Line Medication Selection for Older Adults with Type 2 Diabetes
May 23, 2024

Drs Medha Munshi and James Bailey offer insights into navigating the type 2 diabetes treatment landscape. They emphasize the importance of prioritizing cardiovascular and renal outcomes when selecting treatments for older adult populations.

Community Perspectives: First-Line Treatment Considerations for Older Adults with Type 2 Diabetes
May 23, 2024

Medha Munshi, MD, and James Bailey, III, MD, FACE, ECNU, discuss the current treatment landscape for type 2 diabetes, and highlight key considerations for the selection of first-line treatments for older adults with this condition.

Impact of Geriatric Syndrome in Older Adults with T2D
May 23, 2024

Key opinion leaders in the management of diabetes define and discuss the impact and complexities of geriatric syndromes in older adults with T2D. They shed light on challenges like cognitive impairment, urinary incontinence, and neuropathy, offering insights into effective diabetes management strategies for this demographic.

Defining Older Adults: Highlighting the Age Spectrum and Role of Care Settings
May 23, 2024

Drs Medha Munshi and James Bailey discuss the definition of older adult patients, considering both chronological age and mental and physical state. They underscore the significance of customizing diabetes treatment to accommodate individual patient abilities, rather than solely basing decisions on age

Burden of T2D and Management Considerations for Older and Younger Adults
May 23, 2024

Medha Munshi, MD, and James Bailey, III, MD, FACE, ECNU, delve into the management and burden of type 2 diabetes (T2D). They shed light on the prevalence of the disease in older adults and its potential health impacts as patients age, while also addressing risk factors and considerations for younger patients as they progress in age.

Tezepelumab Cuts COPD Exacerbation Rate in High-Risk Population: COURSE Trial Highlights with Dave Singh, MD
May 20, 2024

Dave Singh, MD, lead investigator for the phase 2a COURSE trial of tezepelumab in moderate to very severe COPD, highlights the drug's promise in vulnerable groups.

ETHOS Post-Hoc Analysis: Dave Singh, MD, Highlights Breztri Reduction of Cardiopulmonary Risk in COPD
May 20, 2024

The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.